Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (NASDAQ:GH), a precision oncology company, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 8th at 4:05 p.m. ET. Investors can access both live and archived webcasts of the presentation through the investor relations section of Guardant Health's website.
Guardant Health (Nasdaq: GH) announced the approval of equity grants to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The grants include 239,565 restricted stock units (RSUs) awarded to 189 employees and stock options to purchase 23,542 shares granted to two employees.
The RSUs will vest over three years, with one-third vesting annually. The stock options, priced at $41.42 per share, will vest one-third after one year, with remaining shares vesting monthly over 24 months. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Guardant Health (NASDAQ: GH) has announced a strategic partnership with the American Cancer Society (ACS) to expand cancer screening access and promote health equity. The collaboration aims to support ACS's nationwide screening initiatives, including the I Love You, Get Screened campaign, which reached over 313 million impressions in 2024.
The partnership focuses on addressing screening disparities in California, where mammogram screening rates (64%) and colorectal cancer screening rates (60%) lag behind national averages. In 2024, these initiatives resulted in over 555,000 completed screenings and 7,800 cancers detected. The program will provide patient education, screening navigation, transportation support, and language access services to underserved communities.
Guardant Health (Nasdaq: GH), a precision oncology company, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will engage in a fireside chat on August 13th at 9:30 a.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the investor relations section of Guardant Health's website.
Guardant Health (Nasdaq: GH) reported strong Q2 2025 financial results, with total revenue reaching $232.1 million, representing a 31% year-over-year increase. The company raised its 2025 revenue guidance to $915-925 million, projecting 24-25% growth.
Key performance metrics include: Oncology revenue of $158.7M (+22%), Screening revenue of $14.8M with 16,000 Shield tests, and Biopharma & Data revenue of $56M (+28%). The company achieved a non-GAAP gross margin of 66%, up from 60% in Q2 2024.
Notable developments include the introduction of 11 Smart Liquid Biopsy applications for Guardant360 Liquid, Shield's inclusion in NCCN guidelines, and FDA Breakthrough Device Designation for Shield Multi-Cancer Detection. The company expects to reach free cash flow breakeven in Q4 2025 for non-Screening business.
Guardant Health (NASDAQ: GH) has partnered with actor James Van Der Beek to promote awareness about colorectal cancer (CRC) screening and their FDA-approved Shield blood test. Van Der Beek, who was diagnosed with stage 3 CRC at age 46, is speaking publicly for the first time about the importance of screening.
The Shield blood test, approved by the FDA last year, offers a convenient screening option for adults 45+ at average risk for CRC through a simple blood draw. With CRC being the second most deadly cancer in the U.S., causing over 50,000 deaths annually, early detection is crucial as the five-year survival rate exceeds 90% when caught early but drops to 13% in late stages.
The National Comprehensive Cancer Network has included Shield in its updated CRC screening guidelines, potentially improving patient access. This advancement is significant as more than 50 million Americans avoid traditional screening methods due to their unpleasant or inconvenient nature.
Guardant Health (Nasdaq: GH) announced positive results from the RADIOHEAD study, conducted in collaboration with the Parker Institute for Cancer Immunotherapy (PICI). The study evaluated Guardant Reveal, a tissue-free monitoring tool for detecting immunotherapy responses in advanced cancer patients.
The research, published in Cancer Research Communications, analyzed over 500 patients with various advanced solid tumors. Key findings showed that Guardant Reveal could identify non-responders up to 5 months earlier than standard methods. Patients with ≥80% decrease in tumor fraction showed a 75% lower risk of progression. The study covered multiple cancer types, including lung, skin, head and neck, breast, GI, GU, and gynecologic cancers.
Guardant Health (Nasdaq: GH) announced the enrollment of the first patient in the National Cancer Institute's Vanguard Study, which will evaluate the company's Shield Multi-Cancer Detection (MCD) test. The four-year study aims to enroll up to 24,000 participants aged 45-75 who are cancer-free.
The Shield MCD test, which recently received FDA Breakthrough Device Designation, can screen for 10 different cancer types through a simple blood draw. The test was selected based on its performance in detecting lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver, and gastric cancers. The study's results will inform the design of a larger randomized controlled trial for cancer screening evaluation.
Guardant Health (NASDAQ: GH), a precision oncology company, has scheduled its Q2 2025 earnings release for July 30, 2025, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day.
The earnings webcast will be accessible through the Investors section of Guardant Health's website, with a replay available after the event.